NEUROMODULATION IN BRAIN FUNCTIONAL DISORDERS: TECHNOLOGICAL FRONTIERS, CLINICAL PARADIGMS, AND THE FUTURE OF NEURAL CIRCUIT INTERVENTIONS: A NARRATIVE REVIEW

Abstract

Introduction Neurological disorders affect over 3 billion people globally and represent the leading cause of disability and mortality worldwide. Conventional pharmacotherapies often fail in treatment-resistant cases, necessitating innovative circuit-based interventions. Neuromodulation, including deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), spinal cord stimulation (SCS), vagus nerve stimulation (VNS), and responsive neurostimulation (RNS) has emerged as a transformative therapeutic paradigm for brain functional disorders. Methods This narrative review synthesizes recent clinical trials, systematic reviews, and technological advancements (2024–2026) in invasive and non-invasive neuromodulation. Emphasis was placed on adaptive closed-loop systems, personalized targeting strategies, waveform innovations, and integration of artificial intelligence (AI) in therapeutic modulation across movement disorders, depression, chronic pain, epilepsy, and systemic inflammatory conditions. Results Adaptive DBS demonstrated significant improvements in “on” time without dyskinesia and reduced energy consumption compared to conventional stimulation. Functional magnetic resonance imaging (fMRI) guided TMS improved response rates in treatment-resistant depression (77.5% vs. 62.2% with standard targeting). Closed-loop SCS using Evoked Compound Action Potential (ECAP) sensing provided stable pain control, while novel waveforms such as Differential Target Multiplexed (DTM) enhanced modulation of neuron–glial interactions. Non-invasive VNS showed promising anti-inflammatory and analgesic effects. In epilepsy, RNS achieved progressive seizure reduction up to 75% over long-term follow-up. AI-driven closed-loop systems and neuromorphic computing enabling real-time signal decoding and personalized stimulation adjustments. Conclusion Neuromodulation is transitioning from static, symptom-based therapy to precision, adaptive circuit intervention. Integration of closed-loop technology and AI promises improved efficacy, reduced adverse effects, and expanded indications. Ensuring equitable access and ethical oversight will be essential as these technologies redefine the future of brain disorder management.